Hi guys. I've held GCG for a few years now.
So the testing business is around a quarter of group NPAT? I wonder if that is substantial enough a divestment to require shareholder approval?
I agree with Lara - the testing business is easy money. Would need a pretty good business case to divest. Though if they can get $15m for a <$2m NPAT business then that is compelling.
Makes you question the $15m though given GCG's P/E as a diversified business.
